Successful MDR-TB Treatment Regimens Including Amikacin are Associated with High Rates of Hearing Loss

Authors

Chawangwa Modongo, University of Pennsylvania
Rafal S. Sobota, Dartmouth College
Boikobo Kesenogile, University of Botswana
Ronald Ncube, Ministry of Health

Document Type

Article

Publication Date

10-9-2014

Publication Title

BioMed Central Infectious Diseases

Department

Geisel School of Medicine

Abstract

Aminoglycosides are a critical component of multidrug-resistant tuberculosis (MDR-TB) treatment but data on their efficacy and adverse effects in Botswana is scarce. We determined the effect of amikacin on treatment outcomes and development of hearing loss in MDR-TB patients. Patients started on MDR-TB treatment between 2006 and 2012 were included. Multivariate analysis was used to determine the effect of amikacin on treatment outcomes and development of hearing loss.

DOI

10.1186/1471-2334-14-542

Comments

Chawangwa Modongo;Rafal S Sobota;Boikobo Kesenogile;Ronald Ncube;Giorgio Sirugo;Scott M Williams;Nicola M Zetola

Dartmouth Digital Commons Citation

Modongo, Chawangwa; Sobota, Rafal S.; Kesenogile, Boikobo; and Ncube, Ronald, "Successful MDR-TB Treatment Regimens Including Amikacin are Associated with High Rates of Hearing Loss" (2014). Dartmouth Scholarship. 627.
https://digitalcommons.dartmouth.edu/facoa/627